Ionizable Lipid Products
Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.
Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.
Built for ionizable-lipid discovery and RNA delivery research
DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.
Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.
Learn about cationic and ionizable lipids →From proprietary lipid design to GMP-grade custom synthesis
DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.
We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.
Discuss a co-development project →Explore New ionizable lipids
Explore our five most recently added ionizable lipids, with specifications, pricing and literature-linked product information.
A selective α2A receptor agonist that can reduce peripheral sympathetic outflow and thus cansues a reduction in peripheral sympathetic tone; a sympatholytic agent used to treat hypertension and attention deficit hyperactivity disorder (ADHD).HypertensionApproved
A selective inhibitor of 26S proteasome subunit Rpn11 with IC50 of 10±2 uM; shows no activity for other DUBs (USP1/USP2/USP4/USP5/USP7/USP8/USP20/UCH37, IC50>50 uM); blocks cellular proteasome function, induces apoptosis in MM cells and overcomes resistance to proteasome inhibitor bortezomib, activates caspase cascade and endoplasmic stress response signaling; reduces progression of tumor growth and prolongs survival in mice MM xenograft model.
A reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM; an anticoagulant agent used to prevent stroke with atrial fibrillation.ThrombosisApproved
A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM; shows no affinity for CCR1, CCR2b, CCR3, CCR4, or CCR7; inhibits the replication of 6 CCR5-using (R5) HIV-1 clinical isolates in peripheral blood mononuclear cells (PBMCs) with mean EC90 of 13 nM; selectively inhibits R5 HIV-1 replication by interfering with coreceptor-mediated entry of the virus into host cells; exhibits a good pharmacokinetic profile in monkeys.HIV InfectionPhase 1 Clinical
A potent, specific and allosteric mGluR1 antagonist with IC50 of 6 nM and 1.4 nM for human and mouse mGluR1, respectively.
A potent, small molecule fetal hemoglobin (HbF) inducer with EC50 of 100 nM; At 100 nM, increases γ-globin expression (2.9- and 3.7-fold increase in KU812 cell and K562 cell, respectively) to higher levels than 50–100 uM hydroxyurea; a useful starting point for the generation of compounds that can be used for the treatment of SCD.
A potent, selective ubiquitin-specific protease USP8 inhibitor with IC50 of 0.85 uM; shows no inhibitory activity for USP7 (IC50>100 uM).
A potent, selective ubiquitin-specific protease USP8 inhibitor with IC50 of 0.56 uM; shows no inhibitory activity for USP7, USP5, SENP1, Uch-L3, and caspase 3 (IC50>100 uM), and displays partial activity against Uch-L3; inhibits the viability of HCT116 colon and PC-3 prostate cancer cell lines with IC50 values in the 0.5-1.5 uM range.
A potent, selective thrombopoietin (TPO) receptor agonist.
A potent, selective small molecule Mcl-1 inhibitor that selectively targets the BH3-binding groove of Mcl-1; effectively competes with FITC-MCL-1 SAHBA and FITC-BID BH3 for MCL-1ΔNΔC binding with IC50 of 4.7 and 4.8 uM, respectively; shows no activity for Bcl-xL; induces caspase activation and leukemia cell death in the specific context of MCL-1 dependence.
A potent, selective receptor interacting protein-2 (RIP2) kinase inhibitor.
A potent, picomolar, dual inhibitor of Aurora A and B with IC50 of 0.02 and 0.03 nM, respectively; shows improved cell potency (phos-HH3 inhibition IC50=25 nM) and intrinsic aqueous solubility (11.4 mM); emonstrated efficacy and target engagement in human tumor xenograft mouse models.
A potent, functionally selective, CNS-penetrating and orally bioavailable inverse agonist of benzodiazepine site of GABAA α5 receptor with Ki of 0.8-1.5 nM for α1-, α2-, α3-, andα5-containing GABAA receptors; has inverse agonist efficacy selective for the α5 subtype, increases long-term potentiation in mouse hippocampal slices; enhances performance in animal models of cognition, does not exhibit the convulsant, proconvulsant, or anxiogenic activity associated with nonselective GABAA inverse agonists.
A potent, dual receptor tyrosine kinase/Src kinase inhibitor with IC50 of 2-16 nM for VEGFR, FGFR and PDGFR, 0.1-5 nM for Src family; inhibits vascular endothelial cell proliferation in vitro (ED50=610 nM) and blocks VEGF-induced phosphorylation of ERK, induces apoptosis; significant suppresses laser-induced choroidal neovascularization (CNV) in a murine model.
A potent, dual receptor tyrosine kinase/Src kinase inhibitor with IC50 of 2-16 nM for VEGFR, FGFR and PDGFR, 0.1-5 nM for Src family; inhibits vascular endothelial cell proliferation in vitro (ED50=610 nM) and blocks VEGF-induced phosphorylation of ERK, induces apoptosis; significant suppresses laser-induced choroidal neovascularization (CNV) in a murine model.
A potent, and selective FAAH inhibitor with IC50 of 18 nM; shows exceptional selectivity and no off-target activity with respect to other serine hydrolases.
A potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays; also inhibits Lyn, and to a lesser extent, FGFR3, and inhibits KIT gain-of-function mutants V559D (IC50=3.0 nM) and Δ27 mouse mutant (IC50=5 nM); dose-dependently inhibits SCF-induced cell proliferation in Ba/F3 cells expressing human wild-type KIT (IC50=150 nM); inhibits tumour growth in vivo.Prostate cancerPhase 3 Clinical
A potent Src inhibitor extracted from patent WO/2012003544A1.
A potent PDE4 inhibitor with IC50 of 94.5 nM.
A potent mutant Src T338C inhibitor with IC50 of 111 nM; exhibited 10-fold selectivity over WT c-Src.
Page 314 of 334 · Browse all 6677 products
Jump to a product page
Featured literature product: HX1 · DCL0028
HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.
Read full formulation and performance →